A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...

A novel blood test analyzing fragments of cell-free DNA showed robust diagnostic performance for colorectal cancer across clinical subgroups, offering a promising noninvasive screening method.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation ...

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

Natera Inc., a cell-free DNA and precision medicine company, has acquired Foresight Diagnostics, a leader in ultrasensitive ...

An Austin, Texas-based genetics-testing company that specializes in cell-free DNA and precision medicine has acquired Foresight Diagnostics Inc., a Boulder-based cancer-diagnostics company.

An Arizona veteran who learned he has ALS is exploring a new blood test that researchers at UCLA are studying.

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

The market offers significant opportunities in non-invasive cancer diagnostics using in vitro blood tests, with potential to replace traditional biopsies. Key areas include screening, diagnosis, ...